Gilead Sciences, Inc. (FRA:GIS)

Market Cap	148.24B +32.5%
Revenue (ttm)	24.79B +2.8%
Net Income	6.91B +6,336.5%
EPS	5.47 +6,514.1%
Shares Out	n/a
PE Ratio	21.45
Forward PE	17.45
Dividend	2.76 (2.33%)
Ex-Dividend Date	Dec 15, 2025

Volume	1,048
Average Volume	426
Open	116.12
Previous Close	117.10
Day's Range	116.12 - 118.22
52-Week Range	82.61 - 118.22
Beta	n/a
RSI	75.29
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GIS

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD